SOHM, Inc. (SHMN) Stock Analysis

SOHM, Inc. (SHMN) Healthcare & Pipeline Overview

SOHM, Inc. develops, manufactures, and distributes generic pharmaceuticals and over-the-counter products in the United States. With a focus on analgesics, antibiotics, and cosmeceuticals, the company caters to both retail and export markets, facing competition in the generic drug sector while maintaining a negative P/E ratio of -2.98.

What Is the Investment Thesis for SHMN?

SOHM, Inc. presents a speculative investment opportunity within the generic pharmaceutical sector. The company's focus on generic drugs and OTC products caters to a market segment seeking affordable healthcare solutions. However, its negative P/E ratio of -2.98 and a profit margin of -73.9% indicate significant financial challenges. A key value driver would be the successful expansion of its product line and market reach, particularly in export markets. Growth catalysts include potential partnerships with larger pharmaceutical distributors and the introduction of new generic drugs to capitalize on patent expirations of branded medications. Potential risks include intense competition, regulatory hurdles, and the company's current financial instability. Investors should closely monitor SOHM, Inc.'s ability to improve its financial performance and navigate the competitive landscape.

Based on FMP financials and quantitative analysis

SHMN Key Highlights

Gross Margin of 71.0% indicates strong pricing power on its products.

• Beta of 0.84 suggests lower volatility compared to the overall market.
• Market Cap of $1.26M reflects its status as a micro-cap company.
• Profit Margin of -73.9% indicates significant financial challenges.
• P/E Ratio of -2.98 suggests the company is currently not profitable.

Who Are SHMN's Competitors?

SHMN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SHMN's Key Strengths?

Diverse product portfolio of generic drugs and OTC products.

• Established manufacturing capabilities.
• Distribution network in the United States.
• Ability to offer private label products.

What Are SHMN's Weaknesses?

Negative profit margin and financial instability.

• Limited brand recognition compared to larger pharmaceutical companies.
• Dependence on generic drug pricing, which is subject to competitive pressures.
• Smaller scale of operations compared to major competitors.

What Could Drive SHMN Stock Higher?

Potential partnerships with larger pharmaceutical distributors to expand market reach.

• Introduction of new generic drugs to capitalize on patent expirations.
• Efforts to improve manufacturing efficiency and reduce production costs.
• Expansion into new geographic markets, particularly in developing countries.
• Development and marketing of over-the-counter (OTC) products.

What Are the Key Risks for SHMN?

Financial-distress signal — its Altman Z-Score of -0.55 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-36.4%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Intense competition from larger generic drug manufacturers.
• Stringent regulatory requirements and compliance costs.
• Pricing pressures and erosion of profit margins.
• Product liability claims.
• Dependence on key suppliers for raw materials.

What Are the Growth Opportunities for SHMN?

• Expansion into New Geographic Markets: SOHM, Inc. can pursue growth by expanding its distribution network into new international markets, particularly in developing countries where demand for affordable generic medications is high. This strategy involves conducting market research to identify suitable regions, establishing partnerships with local distributors, and adapting product offerings to meet local regulatory requirements. The global generics market is expected to continue growing, offering a substantial opportunity for SOHM, Inc. to increase its revenue streams. Timeline: Within the next 2-3 years.
• Development of New Generic Formulations: SOHM, Inc. can invest in research and development to create new generic formulations of existing drugs as their patents expire. This strategy involves identifying promising drug candidates, conducting bioequivalence studies, and obtaining regulatory approvals. Successful development and launch of new generic drugs can significantly boost SOHM, Inc.'s revenue and market share. The market for off-patent drugs is substantial and continuously expanding. Timeline: Ongoing, with new product launches every 12-18 months.
• Strategic Partnerships and Acquisitions: SOHM, Inc. can explore strategic partnerships or acquisitions to expand its product portfolio, enhance its manufacturing capabilities, or gain access to new markets. This strategy involves identifying suitable targets, conducting due diligence, and negotiating favorable terms. Successful partnerships or acquisitions can accelerate SOHM, Inc.'s growth and improve its competitive position. The pharmaceutical industry is characterized by frequent mergers and acquisitions. Timeline: Opportunistic, based on market conditions.
• Focus on Over-the-Counter (OTC) Product Development: SOHM, Inc. can increase its focus on developing and marketing over-the-counter (OTC) products, which offer higher profit margins and less regulatory scrutiny compared to prescription drugs. This strategy involves identifying consumer needs, formulating effective OTC products, and establishing strong branding and marketing campaigns. The OTC market is growing steadily, driven by increasing consumer self-care trends. Timeline: Within the next 1-2 years.
• Enhancement of Manufacturing Efficiency: SOHM, Inc. can improve its manufacturing efficiency to reduce production costs and increase profitability. This strategy involves investing in new equipment, optimizing production processes, and implementing lean manufacturing principles. Lower production costs can enable SOHM, Inc. to offer more competitive pricing and increase its market share. The pharmaceutical industry is constantly seeking ways to improve efficiency and reduce costs. Timeline: Ongoing, with continuous improvement initiatives.

What Are SHMN's Competitive Advantages?

• Formulary knowledge and expertise in generic drug development.
• Established manufacturing capabilities for producing a range of pharmaceutical products.
• Existing distribution network for reaching wholesale and retail customers.
• Ability to offer private label products, providing a customized solution for retailers.

What Does SHMN Do?

SOHM, Inc., established in 2005 and headquartered in Corona, California, operates as a developer, manufacturer, marketer, and distributor of generic and private label pharmaceutical products. The company's portfolio includes a variety of medications such as analgesics, antibiotics, anti-cold remedies, and anti-inflammatory drugs. Additionally, SOHM, Inc. offers over-the-counter (OTC) products, cosmeceuticals, and nutraceuticals, catering to a broad consumer base. The company's business model encompasses both domestic sales within the United States and exports to international markets. SOHM, Inc.'s founding vision was to provide affordable healthcare solutions through generic medications. Over the years, the company has expanded its product line to include a diverse range of pharmaceutical and healthcare-related products. Its strategic focus on generic drugs allows it to compete on price and accessibility, targeting consumers and healthcare providers seeking cost-effective alternatives to brand-name medications. The company's manufacturing processes adhere to industry standards to ensure product quality and safety. Despite its presence in the market, SOHM, Inc. faces challenges typical of the generic drug industry, including pricing pressures, regulatory compliance, and competition from larger pharmaceutical companies. Its ability to innovate and adapt to changing market dynamics will be crucial for sustained growth and profitability. The company's current market capitalization is $0.00B, reflecting its position within the competitive landscape.

What Products and Services Does SHMN Offer?

• Develops generic pharmaceutical products.
• Manufactures generic drugs.
• Markets generic medications to wholesalers and retailers.
• Distributes generic drugs across the United States.
• Offers private label pharmaceutical products.
• Exports pharmaceutical products to international markets.
• Provides over-the-counter (OTC) medications.

How Does SHMN Make Money?

• Develops and manufactures generic drugs to sell at lower prices than branded medications.
• Markets and distributes its products through wholesale distributors, retail pharmacies, and export channels.
• Generates revenue from the sale of generic and private label pharmaceutical products.

What Industry Does SHMN Operate In?

SOHM, Inc. operates within the competitive generic pharmaceutical industry, characterized by pricing pressures and stringent regulatory requirements. Key competitors include larger generic drug manufacturers and companies with established distribution networks. SOHM, Inc. differentiates itself through its focus on private label products and its ability to export medications, but must navigate intense competition from companies like ANTCF (Antibe Therapeutics Inc.) and BHNGF ( বেঙ্গল গ্লাস ওয়ার্কস লিমিটেড).

Who Are SHMN's Key Customers?

• Wholesale drug distributors.
• Retail pharmacies.
• Hospitals and healthcare providers.
• Export markets in various countries.
• Consumers purchasing over-the-counter medications.

Company Profile

SOHM, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Corona, US. The company is led by CEO Baron Night. SHMN has traded publicly since 2010.

SOHM, Inc. (SHMN) Valuation Context

Valued at $1.26M, SHMN is classified as a micro-cap stock.

Return on equity for SOHM, Inc. stands at -36.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -10.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -41.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.08 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -31.7%, the inverse of the P/E and a quick read on earnings relative to price.

SOHM, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.55 places it in the distress zone, a signal of elevated financial risk.

SHMN Financials

SHMN Latest News

No recent news available for SHMN.

SHMN Analyst Consensus

SHMN MoonshotScore

SHMN Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources